Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis

Area of Science:

• Pulmonology
• Fibrotic Interstitial Lung Diseases

Background:

• Idiopathic pulmonary fibrosis (IPF) and other diffuse interstitial lung diseases (ILDs) can present with progressive pulmonary fibrosis (PPF).
• PPF is a clinical condition characterized by worsening fibrosis that impacts patient prognosis across various ILDs.

Purpose of the Study:

• To define progressive pulmonary fibrosis (PPF) as a clinical behavior in fibrosing diffuse interstitial lung diseases (ILDs).
• To highlight the role of antifibrotic therapies in managing PPF.

Main Methods:

• Identification of PPF through worsening clinical, physiological, and radiological criteria during patient follow-up.
• Review of randomized clinical trials evaluating antifibrotic drugs in IPF and progressive non-IPF ILD.

Main Results:

• Antifibrotic drugs, nintedanib and pirfenidone, have demonstrated efficacy in slowing disease progression in patients with IPF and progressive non-IPF ILD.
• PPF represents a common clinical endpoint in fibrosing ILDs, irrespective of the specific underlying entity.

Conclusions:

• Progressive pulmonary fibrosis (PPF) is a critical clinical condition requiring dedicated management strategies within the spectrum of diffuse interstitial lung diseases (ILDs).
• The advent of antifibrotic therapies marks a new era for managing patients with PPF, offering improved prognostic outcomes.